Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

Inclusion Criteria:

- Men and women, ages 18 to 70 years.

- Participants infected with hepatitis C virus (HCV) genotype 1, 2, or 3, with no
previous exposure to an interferon formulation (ie, interferon-alpha, pegylated
interferon-alpha) ribavirin, or other HCV-specific direct-acting antiviral (including
daclatasvir and PSI-7977).

- Patients should have chronic hepatitis C genotype 1a, 1b, 2, or 3 as documented by:
positive test results for anti-HCV antibody; HCV RNA; or a HCV genotype at least 6
months prior to screening, and HCV RNA and anti-HCV antibody at the time of
screening.

Exclusion Criteria:

- Evidence of a medical condition associate with chronic liver disease other than HCV.

- History of variceal bleeding, hepatic encephalopathy, or ascites requiring management
with diuretics or paracentesis.

- History of hemophilia.

- History of torsade de pointes.

- Current or known history of cancer (except in situ carcinoma of the cervix or
adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior
to enrollment.

- History of gastrointestinal disease or surgical procedure (except cholecystectomy).

- History of clinically significant cardiac disease.

- Blood transfusion within 4 weeks prior to study drug administration.

- Poor venous access.

- Any other medical, psychiatric, and/or social reason which, in the opinion of the
Investigator, would make the candidate inappropriate for participation in this study.